The research, led by Ralph Baric, PhD, professor of epidemiology at UNC's Gillings School of Global Public Health, comes on the heels of two recent high-profile outbreaks, Ebola and Zika for which there are no vaccines. The two outbreaks combined claimed thousands of lives and cost billions in foregone economic growth.
Researcher Vineet Menachery said that the capacity of this group of viruses to jump into humans is greater than we originally thought, adding that while other adaptations may be required to produce an epidemic, several viral strains circulating in bat populations have already overcome the barrier of replication in human cells and suggest reemergence as a distinct possibility.
He further said that this virus may never jump to humans, but if it does, WIV1-CoV has the potential to seed a new outbreak with significant consequences for both public health and the global economy.
The research team also found that antibodies developed to treat SARS were effective in both human and animal tissue samples against WIV1-CoV, providing a potent treatment option if there were an outbreak.
However, the limitation to treat with antibodies is the same as with ZMapp, the antibody approach used for Ebola: producing it at a large enough scale to treat many people.
Also, in terms of prevention, existing vaccines against SARS would not provide protection for this new virus due to slight differences in the viral sequence.
The study is published in the journal of Proceedings of the National Academy of Sciences.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.